Why Is 4D Molecular Therapeutics Stock Gaining Monday? - 4D Molecular Therapeutics (NASDAQ:FDMT)
4D Molecular Therapeutics (FDMT) shares rose after Phase 2b results for 4D-150 in wet AMD. In 45 patients, the 3E10 vg/eye dose was chosen for Phase 3. As of May 18, 2026, it maintained visual acuity and reduced treatment burden 78% vs projected aflibercept injections, with 2.8% mild inflammation. Phase 3 enrollment completed; topline expected 2027. HC Wainwright reiterated Buy, $36 target.
How this was made
The 30-second read
Why it matters
The disclosed Phase 2b maintenance of visual acuity, central subfield thickness control, and large reduction in treatment burden supports the chosen Phase 3 dose (3E10 vg/eye). Enrollment completion in both Phase 3 trials reduces near-term execution risk, but the primary decision catalyst remains 2027 topline data.
Market read
Investors are reacting to supportive Phase 2b durability and burden-reduction data that justify the Phase 3 dose, plus completion of enrollment in both Phase 3 studies.
What to watch
The article does not provide Phase 3 primary endpoint results, effect size versus aflibercept, or any new manufacturing/financing updates that could materially change risk.
Background
FDMT’s 4D-150 is being advanced in wet AMD via two Phase 3 trials (4FRONT-1 and 4FRONT-2) after Phase 2b dose selection.
Ticker impact
FDMT shares rose premarket as Phase 2b 4D-150 data supported the 3E10 vg/eye dose for two Phase 3 trials, with topline expected in 2027.
Near-term upside bias likely persists while investors digest Phase 3 readiness and the reiterated Buy/PT, but the next major catalyst is 2027 topline.
The newest concrete facts are Phase 2b efficacy and burden reduction supporting the Phase 3 dose, plus completion of enrollment in 4FRONT-1 and 4FRONT-2. These are supportive, but not a new Phase 3 efficacy datapoint or regulatory milestone.
Market effects
Supports sentiment for intravitreal gene therapy and retinal disease development programs by highlighting durable visual acuity maintenance and reduced injection burden.
Limited, primarily affects US biotech/gene-therapy sentiment rather than broader regional risk.
Phase 3 trials are described as global, but no new international regulatory or partnership details are provided.
Counterpoint
Durability and safety in Phase 2b do not guarantee Phase 3 efficacy magnitude versus comparators, so the stock may be vulnerable to any Phase 3 design or endpoint surprises.
Key entities
- company4D Molecular Therapeutics
NASDAQ-listed developer of 4D-150 for wet age-related macular degeneration; stock is up premarket on Phase 2b and Phase 3 readiness updates.
- product4D-150
Intravitreal therapy evaluated in Phase 2b and advanced into two Phase 3 trials with topline expected in 2027.
- clinical_program4FRONT-1
Phase 3 trial for wet AMD; enrollment completed in February, topline expected first half of 2027.
- clinical_program4FRONT-2
Second Phase 3 trial in the global program; enrollment completed in June, topline expected second half of 2027.
- analyst_firmHC Wainwright & Co.
Analyst Matthew Caufield reiterated a Buy and maintained a $36 price forecast.
